Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
109Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $33.03M | $-44.63M | $-0.42 |
| 2024 | $38.63M | $-41.05M | $-0.39 |
| 2023 | $41.29M | $-37.92M | $-0.37 |
| 2022 | $44.26M | $-23.57M | $-0.19 |
| 2021 | $33.89M | $-19.08M | $-0.22 |
Social Signal Score
Earnings
Wed, Nov 11(in 3 months)
Consensus estimate $-0.08 per share
Typical surprise +11.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.08 vs $-0.09beat
- Tue, May 12$-0.04 vs $-0.10beat
- Tue, Mar 24$-0.06 vs $-0.08beat
- Wed, Nov 12$-0.12 vs $-0.11miss
- Wed, Aug 6$-0.12 vs $-0.10miss
- Wed, May 7$-0.10 vs $-0.10beat
Estimates and results for MXCT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
MXCThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (3)
- Newsmarketbeat.com·2d ago·Neutral
MaxCyte Q2 Earnings Call Highlights MaxCyte NASDAQ: MXCT reported second-quarter 2026 revenue of $7.3 million, down 15% from $8.5 million a year earlier, as lower license revenue, timing of instrument placements and prior-year processing assembly purchases affected results. Management said the quarter came in ahead of its expectations and represented progress toward stabilizing the business before returning to growth in the second half of the year.
View source ↗ - Newsseekingalpha.com·2d ago·Positive
MaxCyte, Inc. (MXCT) Q2 2026 Earnings Call Transcript MaxCyte, Inc. (MXCT) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·2d ago·Neutral
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.12 per share a year ago.
View source ↗